Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Mesenchymal Stem Cells for Advanced Cerebral Adrenoleukodystrophy
NCT02410239Phase 1Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in cerebral adrenoleukodystrophy (CALD), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Jun 2015; status: withdrawn.
02
Drugs
mesenchymal stem cells
03
Conditions
cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on NCT02410239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410239.